source
- Verdiva Bio halts phase 2 oral GLP-1 trial after enrolling only eight participantsVerdiva Bio announced it is ending its phase 2 study of VRB-101, a once‑weekly oral GLP‑1 candidate, after the trial fell far short of its enrollment target. The study was intended to evaluate swi…
- FTC seeks contempt ruling against Martin Shkreli for breaching lifetime pharma banThe Federal Trade Commission has asked a judge to hold Martin Shkreli in contempt for allegedly breaching the lifetime ban that was imposed after his 2022 release from prison. The agency alleges t…